2 results
Approved WMOCompleted
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
Approved WMOCompleted
Primary:To characterize the dose response of nemiralisib administered in addition to SoC (standard of care) compared with placebo and SoC in participants diagnosed with an acute moderate or severe exacerbation of COPD. Secondary:Dose response and…